Loading…
Login
Scholar Register
Business Register
Subscribe
Loading…
Article Title
Abstract
Keyword
Category
MESH Heading
Grant Agency
RCAID
DOI
PMID
PMCID
Author
Affiliation
Email
Journal Title
ISSN
Publisher
Loading…
Contains
Equals
Find an Article
Find an Article (55347805)
Find a Category (124)
Find a Journal (6144)
Find a Scholar (3970)
Find an Academic Assistant (17)
Find an Article PDF (4612468)
Today's Articles (73)
Subscriber (49385)
Citation(s) in
RCA
2
(from Reference Citation Analysis)
Indexed Articles
Today (0)
Yesterday (0)
This Week (0)
Last Week (0)
Current Month (0)
Last Month (0)
Ranked By
Impact Index Per Article
Citation(s) in
RCA
Results Analysis
Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis
Results Analysis
Year Published
2024 (1)
2019 (1)
Show more
Refine
Article Statistics
PubMed (2)
RCA (2)
SCIE (2)
Open (1)
Refine
Publication Titles
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (1)
EXPERT REVIEW OF HEMATOLOGY (1)
Show more
Refine
Category
Hematology (1)
Pharmacology & Pharmacy (1)
Show more
Refine
For:
Eskazan AE
.
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Cancer
2018;
124
:4260-4261. [PMID:
30276792
DOI:
10.1002/cncr.31682
]
[
Citation(s) in
RCA
: 1
]
[
Impact Index Per Article: 0.2
]
[
Reference Citation Analysis
]
[
What about the content of this article? (
0
)
]
[
Track Full Text
]
[
Journal Information
]
[
Subscribe
]
[
Scholar Register
]
[Received: 06/19/2018]
[Accepted: 06/25/2018]
[Indexed: 01/10/2023]
Number
Cited by Other Article(s)
1
Saydan B
, Özmen D, Eşkazan AE. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
Expert Rev Hematol
2024;
17
:275-277. [PMID:
38888284
DOI:
10.1080/17474086.2024.2370556
]
[
Citation(s) in
RCA
: 0
]
[
Impact Index Per Article: 0
]
[
Reference Citation Analysis
]
[
Key Words
]
[
MESH Headings
]
[
Track Full Text
]
[
Journal Information
]
[
Subscribe
]
[
Scholar Register
]
[Received: 04/10/2024]
[Accepted: 06/17/2024]
[Indexed: 06/20/2024]
Abstract
Collapse
Key Words
50 mg
CML
Chronic myeloid leukemia
dasatinib
low-dose
Collapse
MESH Headings
Humans
Dasatinib/therapeutic use
Dasatinib/administration & dosage
Dasatinib/adverse effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
Protein Kinase Inhibitors/therapeutic use
Protein Kinase Inhibitors/administration & dosage
Protein Kinase Inhibitors/adverse effects
Antineoplastic Agents/therapeutic use
Antineoplastic Agents/administration & dosage
Antineoplastic Agents/adverse effects
Treatment Outcome
Collapse
Grants
Collapse
Affiliation(s)
Betül Saydan
Faculty of Medicine, Ankara University, Ankara, Turkey
Deniz Özmen
Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
Ahmet Emre Eşkazan
Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey
Collapse
2
Eşkazan AE
. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?
Br J Clin Pharmacol
2019;
85
:2241-2243. [PMID:
31393022
PMCID:
PMC6783590
DOI:
10.1111/bcp.14092
]
[
Citation(s) in
RCA
: 6
]
[
Impact Index Per Article: 1.2
]
[
Reference Citation Analysis
]
[
Key Words
]
[
MESH Headings
]
[
Track Full Text
]
[
Journal Information
]
[
Subscribe
]
[
Scholar Register
]
[Received: 04/23/2019]
[Revised: 08/06/2019]
[Accepted: 08/06/2019]
[Indexed: 12/18/2022]
Open
Abstract
Collapse
Key Words
adverse event
chronic myeloid leukaemia
haematologic toxicity
tyrosine kinase inhibitor
Collapse
MESH Headings
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Network Meta-Analysis
Protein Kinase Inhibitors
Collapse
Grants
Collapse
Affiliation(s)
Ahmet Emre Eşkazan
Cerrahpasa Faculty of Medicine, Department of Internal Medicine, Division of Hematology
Istanbul University—Cerrahpasa
Istanbul
Turkey
Collapse
Page 1 of 1
1
Loading…
Loading…
Export Articles to File
Export Citation Analysis
Export Citation Analysis
Article Number From
to
A maximum of 600 records can be exported at a time.
Format:
*
Excel
Plain Text
PDF
WORD
Invalid value
Loading…
Click to Download the Exported File
Loading…
Loading…
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Select the Category
Loading…
Loading…
Impact Index Per Article
Calculation for Impact Index Per Article
Times Cited ÷ Number of Years = Impact Index Per Article
TM
Loading…
